DB17275ExperimentalProtein Based Therapies
ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.
- Mechanism
- Curator reviewed
Pharmacologically active on Gastrin-releasing peptide receptor, Neuromedin-B receptor, and Bombesin receptor subtype-3
- Code names
- ST-36
Resolves to
What you can answer from here — as of July 08, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with ST-36, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account